Source:
associated press– 1 hour ago
WASHINGTON (AP) — Government health officials Wednesday publicly aired deep differences over the safety of long-acting asthma drugs and called on outside medical and scientific advisers to help settle the issue.
Experts from the Food and Drug Administration's safety office are recommending that medications like Advair and Symbicort no longer be used to treat children with asthma because of the risk of serious breathing problems. But the FDA office that oversees respiratory drugs says most patients benefit from the medications, and the risks can be addressed through warnings and educational materials for patients and doctors.
The widely used medications already carry strong government warnings. The advisers — some 30 experts representing respiratory, safety and pediatric specialties — will vote Thursday on whether the risks of the drugs outweigh their benefits for children, teens and adults.
~snip~
At issue are four inhaler medications: Advair, Foradil, Serevent and Symbicort. A review panel from the FDA safety office is recommending that Foradil and Serevent no longer be used for asthma in any patients, and that none of the drugs be used by children 17 and under.
Read more:
http://www.google.com/hostednews/ap/article/ALeqM5jbqSdtKeYfs2ebIdlNs0oatLHj3wD94VUIV81